Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/8408
Title: Study protocol and statistical analysis plan for the Liberal Glucose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes (LUCID) trial.
Authors: Poole, Alexis P
Finnis, Mark E
Anstey, James
Bellomo, Rinaldo
Bihari, Shailesh
Biradar, Vishwanath
Doherty, Sarah
Eastwood, Glenn
Finfer, Simon
French, Craig J
Ghosh, Angaj
Heller, Simon
Horowitz, Michael
Kar, Palash
Kruger, Peter S
Maiden, Matthew J
MÃ¥rtensson, Johan
McArthur, Colin J
McGuinness, Shay P
Secombe, Paul J
Tobin, Antony E
Udy, Andrew A
Young, Paul J
Deane, Adam M
Citation: Crit Care Resusc. 2020 Jun;22(2):133-141.
Abstract: BACKGROUND: Contemporary glucose management of intensive care unit (ICU) patients with type 2 diabetes is based on trial data derived predominantly from patients without type 2 diabetes. This is despite the recognition that patients with type 2 diabetes may be relatively more tolerant of hyperglycaemia and more susceptible to hypoglycaemia. It is uncertain whether glucose targets should be more liberal in patients with type 2 diabetes. OBJECTIVE: To detail the protocol, analysis and reporting plans for a randomised clinical trial - the Liberal Glucose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes (LUCID) trial - which will evaluate the risks and benefits of targeting a higher blood glucose range in patients with type 2 diabetes. DESIGN, SETTING, PARTICIPANTS AND INTERVENTION: A multicentre, parallel group, open label phase 2B randomised controlled clinical trial of 450 critically ill patients with type 2 diabetes. Patients will be randomised 1:1 to liberal blood glucose (target 10.0-14.0 mmol/L) or usual care (target 6.0-10.0 mmol/L). MAIN OUTCOME MEASURES: The primary endpoint is incident hypoglycaemia (< 4.0 mmol/L) during the study intervention. Secondary endpoints include biochemical and feasibility outcomes. RESULTS AND CONCLUSION: The study protocol and statistical analysis plan described will delineate conduct and analysis of the trial, such that analytical and reporting bias are minimised. TRIAL REGISTRATION: This trial has been registered on the Australian New Zealand Clinical Trials Registry (ACTRN No. 12616001135404) and has been endorsed by the Australian and New Zealand Intensive Care Society Clinical Trials Group.
Click to open Pubmed Article: https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/32389105
Journal title: Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine
Volume: 22
Pages: 133-141
Publication Date: 2020-06
Type: Journal Article
Randomized Controlled Trial
URI: https://hdl.handle.net/10137/8408
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing

Pubmed

PubMed References

Who's citing